Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07093255
PHASE1
Safety, PK and PD of FLQ-101 in Premature Neonates
Sponsor: FELIQS INC.
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.
Official title: A Phase 1b, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of FLQ-101 in Premature Neonates at High Risk of Developing ROP
Key Details
Gender
All
Age Range
4 Days - 5 Days
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2025-10-01
Completion Date
2026-12-31
Last Updated
2025-07-30
Healthy Volunteers
No
Conditions
Interventions
DRUG
FLQ-101
The invervention comprises 3 Groups: * Group 1: Low Dose * Group 2: Middle Dose * Group 3: High Dose